Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Abstract

Among patients treated with DAA, SVR was associated with a considerable reduction in the risk of HCC. We did not find any evidence to suggest that DAAs promote HCC. However, in patients with SVR, the absolute risk of HCC remained high in patients with established cirrhosis. These patients should be considered for ongoing HCC surveillance.